Core Viewpoint - China Nuclear Industry's subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has received approval for clinical trial application of its self-developed drug "Injection Boron [10B] Faron" for Boron Neutron Capture Therapy (BNCT), marking a significant advancement in cancer treatment [1] Group 1: Drug Development - The approved drug targets head and neck tumors that are resistant to radiotherapy and chemotherapy, particularly in cases that are recurrent, difficult to treat, infiltrative, and locally metastatic [1] - The treatment regimen is notably short, requiring only 1-2 sessions, and has low toxicity and side effects, representing a significant clinical advantage [1] Group 2: Innovation and Strategic Impact - The approval signifies a breakthrough in the collaborative research and development of BNCT drugs and devices, entering a new phase of clinical transformation [1] - This development aligns with the "Healthy China" strategy, injecting new momentum from nuclear technology into precision cancer treatment and contributing a "Chinese solution" to global cancer therapy [1]
中国同辐附属公司中核海得威BNCT硼药获批临床